MetLife Investment Management LLC Sells 364 Shares of United Therapeutics Co. (NASDAQ:UTHR)

MetLife Investment Management LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 1.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 22,982 shares of the biotechnology company’s stock after selling 364 shares during the period. MetLife Investment Management LLC owned approximately 0.05% of United Therapeutics worth $8,236,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in UTHR. Renaissance Technologies LLC grew its stake in United Therapeutics by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after acquiring an additional 22,978 shares during the period. FMR LLC grew its position in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the period. LSV Asset Management increased its stake in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after buying an additional 22,683 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in United Therapeutics by 0.9% in the third quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock valued at $203,078,000 after buying an additional 4,869 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $378.13 on Friday. The stock has a 50-day simple moving average of $366.89 and a 200 day simple moving average of $334.15. The stock has a market capitalization of $16.88 billion, a P/E ratio of 16.61, a PEG ratio of 1.10 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the company posted $5.38 EPS. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. Research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on UTHR shares. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Bank of America lowered their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $370.86.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. This trade represents a 74.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 127,227 shares of company stock worth $47,398,820 over the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.